Executive Summary
Receptor-targeting approach to the activin E obesity pathway - orthogonal to ARO-INHBE
ARO-ALK7
ALK7 · RNAi (siRNA)
Target: ALK7
Full NameACVR1C (Activin A Receptor Type 1C)
PathwayActivin E / ALK7 signaling in adipose tissue
Mechanism of Action
TypeRNAi (siRNA) via TRiM platform
DescriptionARO-ALK7 silences ALK7 (ACVR1C) mRNA in adipose tissue, preventing activin E from signaling through its receptor. This blocks fat accumulation and promotes weight loss through the same pathway as ARO-INHBE.
Indications: ObesityMetabolic Dysfunction
Target Biology
ALK7 is the receptor for activin E in adipose tissue. While ARO-INHBE targets the ligand (activin E), ARO-ALK7 targets the receptor directly. Both approaches should block the same fat-storage pathway.
Clinical Data
ARO-ALK7 Phase 1/2
Phase 1/2 Recruiting Target n=Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| Orthogonal approach to same validated pathway | ALK7 is receptor for INHBE/activin E | Medium |
| Dual program gives optionality | ARWR can advance best candidate | High |
| Earlier stage means less dilution if successful | Phase 1/2 just started | Medium |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Even earlier stage than ARO-INHBE | No clinical data yet | Provides pipeline depth |
| Same GLP-1 competition | Wegovy/Zepbound dominating obesity market | Differentiated mechanism |
| May be redundant with ARO-INHBE | Same pathway targeted differently | Different tissue targeting may yield different profile |
Key Debates
| Question | Bull View | Bear View | Resolution Catalyst |
|---|---|---|---|
| Will ALK7 inhibition show differentiated profile vs ARO-INHBE? | Receptor targeting in adipose may have different efficacy/safety | Same pathway means similar results; one program sufficient | Head-to-head comparison of Phase 1/2 data |
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Phase 1/2 initial data | 2026-2027 | Medium | Weight loss, comparison to ARO-INHBE profile | — |